Phase 2 studies of bortezomib-based regimens in preparation for ASCT
| Regimen . | N . | After induction . | After transplantation . | PFS, median . | OS, 30 mo . | Reference . | ||
|---|---|---|---|---|---|---|---|---|
| CR + PR, % . | CR/ ≥ VGPR, % . | CR + PR, % . | CR / ≥ VGPR, % . | |||||
| V (single agent) | 64 | 41 | NR (9)*/17 | NR | NR | 17 mo | 30 mo, 79% | 49 |
| V ± D | 32 | 87.5 | 6 (25)*/NR | NR | NR | NR | NR | 50 |
| VD | 48 | 66 | NR (21)*/31 | 90 | NR (33)*/55 | NR | NR | 51 |
| V alternated with D | 40 | 65 | 12.5/22.5 | 88 | 33/55 | NR | NR | 52 |
| PAD-1 | 21 | 95 | 24 (5)*/62 | 95 | 43 (14)*/81 | median, 29 mo | 2-yr, 95% | 54 |
| PAD-2 | 20 | 89 | 11 (5)*/42 | 90 | 37 (5)*/53 | median, 24 mo | 2-yr, 73% | 54 |
| VDD | 50 | 78 | NR (27)*/NR | 93 | 27/NR | NR | NR | 56 |
| VDD | 40 | 85 | NR (37.5)*/57.5 | 87 | NR (57)*/77 | 2-yr, 80% | 2-yr, 92% | 57 |
| CyBorD | 33 | 88 | 3 (39)*/61 | NR | NR (70)*/74 | NR | NR | 58 |
| VCD | 391 | 85.4 | NR (15)*/37 | NR | NR | NR | NR | 59 |
| VTD vs VTDC | 49 vs 48 | 100 vs 96 | (29)/69 vs (31)/69 | 100 vs 100 | (50)/87 vs (44)/85 | NR | 1-yr, 94.1% vs 94.2% | 66 |
| TT3 + VTD-PACE vs TT2 + THAL (retrospective comparison) | 303 vs 323 | NR vs NR | NR vs NR | NR vs NR | 2-yr, 54/NR vs 51/NR | 2-yr, 84% vs 77% (P = .008) | 2-yr, 87% vs 83% (P = .12) | 67 |
| Regimen . | N . | After induction . | After transplantation . | PFS, median . | OS, 30 mo . | Reference . | ||
|---|---|---|---|---|---|---|---|---|
| CR + PR, % . | CR/ ≥ VGPR, % . | CR + PR, % . | CR / ≥ VGPR, % . | |||||
| V (single agent) | 64 | 41 | NR (9)*/17 | NR | NR | 17 mo | 30 mo, 79% | 49 |
| V ± D | 32 | 87.5 | 6 (25)*/NR | NR | NR | NR | NR | 50 |
| VD | 48 | 66 | NR (21)*/31 | 90 | NR (33)*/55 | NR | NR | 51 |
| V alternated with D | 40 | 65 | 12.5/22.5 | 88 | 33/55 | NR | NR | 52 |
| PAD-1 | 21 | 95 | 24 (5)*/62 | 95 | 43 (14)*/81 | median, 29 mo | 2-yr, 95% | 54 |
| PAD-2 | 20 | 89 | 11 (5)*/42 | 90 | 37 (5)*/53 | median, 24 mo | 2-yr, 73% | 54 |
| VDD | 50 | 78 | NR (27)*/NR | 93 | 27/NR | NR | NR | 56 |
| VDD | 40 | 85 | NR (37.5)*/57.5 | 87 | NR (57)*/77 | 2-yr, 80% | 2-yr, 92% | 57 |
| CyBorD | 33 | 88 | 3 (39)*/61 | NR | NR (70)*/74 | NR | NR | 58 |
| VCD | 391 | 85.4 | NR (15)*/37 | NR | NR | NR | NR | 59 |
| VTD vs VTDC | 49 vs 48 | 100 vs 96 | (29)/69 vs (31)/69 | 100 vs 100 | (50)/87 vs (44)/85 | NR | 1-yr, 94.1% vs 94.2% | 66 |
| TT3 + VTD-PACE vs TT2 + THAL (retrospective comparison) | 303 vs 323 | NR vs NR | NR vs NR | NR vs NR | 2-yr, 54/NR vs 51/NR | 2-yr, 84% vs 77% (P = .008) | 2-yr, 87% vs 83% (P = .12) | 67 |
CyBorD indicates cyclophosphamide, bortezomib, dexamethasone; D, dexamethasone; NR, not reported; PACE, cisplatin, doxorubicin, cyclophosphamide, etoposide; PAD, bortezomib, doxorubicin, dexamethasone; PAD-2, reduced-dose bortezomib; THAL, thalidomide; TT3, Total Therapy 3; V, bortezomib; VCD, bortezomib, cyclophosphamide, dexamethasone; VDD, bortezomib, pegylated liposomal doxorubicin, dexamethasone; and VTD, bortezomib, thalidomide, dexamethasone.
At least near CR.